Last updated: February 19, 2026
Treximet (sumatriptan and naproxen sodium) is a combination medication used to treat acute migraine attacks. It is marketed primarily by GlaxoSmithKline (GSK) and approved in numerous countries over the years. Its manufacturing involves multiple suppliers across different regions, primarily for active pharmaceutical ingredients (APIs) and excipients.
Who Are the Major Suppliers for Treximet?
Active Pharmaceutical Ingredient (API) Suppliers
Treximet combines two APIs: sumatriptan and naproxen sodium. These components are sourced from specialized chemical manufacturing companies.
| API |
Supplier Companies |
Regions |
Notes |
| Sumatriptan |
Teva Pharmaceutical Industries, Ascendis Pharma, Cipla, Mylan |
Israel, India, USA |
These companies produce generic sumatriptan, approved for Treximet's formulation. |
| Naproxen Sodium |
Solastlot, Ramipharm, Solutia |
India, China, Europe |
Suppliers provide pharmaceutical-grade naproxen sodium. |
Excipients and Other Components
Common excipients (fillers, binders, stabilizers) in Treximet are sourced from global suppliers covering stabilizers and binders, such as:
- Cornstarch
- Lactose
- Magnesium stearate
- Microcrystalline cellulose
Major suppliers include, but are not limited to:
- DuPont
- JRS Pharma
- FMC Corporation
Manufacturing and Supply Chain Dynamics
GSK and Contract Manufacturing
GSK oversees the formulation of Treximet but outsources key manufacturing processes internationally:
- API production primarily from generic manufacturers in India and Israel, with some supply chain contributions from U.S.-based plants.
- Final formulation and packaging handled by GSK’s partner facilities across Europe and North America.
Regulatory and Sourcing Considerations
When considering Treximet’s supply chain:
- Quality standards: Suppliers must meet FDA and EMA regulations, including cGMP compliance.
- Risk factors: Reliance on multiple suppliers helps mitigate production disruptions caused by regulatory issues, political instability, or manufacturing failures.
Key Suppliers with Notable Roles
- Sumatriptan APIs: Teva, Mylan, Cipla.
- Naproxen sodium APIs: Solastlot, Ramipharm.
- Excipients: Suppliers globally recognized for pharmaceutical-grade excipients, such as FMC and DuPont.
Market Trends and Supply Chain Considerations
- Increasing emphasis on regional API manufacturing to reduce dependency on Asian suppliers.
- Growing use of dual sourcing strategies to ensure supply security.
Summary of Supplier Landscape
| Supplier Type |
Key Companies |
Regions |
Notes |
| Sumatriptan API producers |
Teva, Mylan, Cipla |
Israel, India, USA |
Provide APIs for branded and generic Treximet formulations. |
| Naproxen sodium API producers |
Solastlot, Ramipharm |
India, China, Europe |
Supply raw materials compliant with pharmaceutical standards. |
| Excipients |
FMC, DuPont, JRS Pharma |
Global |
Supply stabilizers, fillers, and binders. |
Legal and Regulatory Framework
- Suppliers must adhere to FDA and EMA regulations.
- Supply agreements often specify traceability, batch testing, and certificates of analysis (COA).
- Countries with more stringent regulatory environments tend to influence supplier choices.
Key Takeaways
- Multiple suppliers for sumatriptan and naproxen sodium APIs are involved, mainly from India, Israel, and China.
- Final formulation and packaging are primarily done by GSK or its contract manufacturers in Europe and North America.
- Supply chain resilience depends on diversified sourcing and compliance with regulatory standards.
FAQs
-
Who are the primary API suppliers for Treximet?
- Sumatriptan: Teva, Mylan, Cipla.
- Naproxen sodium: Solastlot, Ramipharm.
-
Are there risks associated with Treximet's supply chain?
- Yes. Dependence on international suppliers can lead to disruptions due to regulatory issues, geopolitical factors, or manufacturing failures.
-
Is Treximet manufactured solely by GSK?
- No. GSK outsources manufacturing to third-party facilities, especially for formulation and packaging.
-
What regulatory standards do suppliers for Treximet need to meet?
- Suppliers must comply with FDA, EMA, and other regional cGMP standards.
-
Are Regional API manufacturing trends affecting Treximet supply?
- Yes. There is an industry trend toward increasing regional API production to minimize dependency on imported raw materials.
References
[1] U.S. Food and Drug Administration (FDA). (2022). API Manufacturing. https://www.fda.gov/drugs/pharmaceutical-quality-resources/api-approvals
[2] European Medicines Agency (EMA). (2022). Supply Chain Regulations. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/supply-chain-regulations
[3] KPMG. (2021). Global Supply Chain Trends in Pharmaceuticals. https://assets.kpmg/content/dam/kpmg/xx/pdf/2021/09/PharmaSupplyChain.pdf
[4] GSK. (2022). Treximet Product Information. https://gskpro.com/content/dam/global/hcpportal/en-US/Prescribing_Guide/T/Treximet/treximet.pdf
